Vertex Pharmaceuticals Incorporated: all 295 studies

Page 3 of 3. Open to participants first (23), then studies with results posted, then the rest; newest registration first within each.

• Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy ParticipantsCompletedNCT05635110Phase 1
• A Phase 1, First-in-human Study of VX-634CompletedNCT05579431Phase 1
• Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic ImpairmentCompletedNCT05560464Phase 1
• A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and DigoxinCompletedNCT05541471Phase 1
• A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/DeutivacaftorCompletedNCT05535959Phase 1
• A Phase 1 Dose Escalation Study of VX-708 in Healthy ParticipantsCompletedNCT05518734Phase 1
• A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548CompletedNCT05455502Phase 1
• A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination TherapyActive, not recruitingNCT05444257Phase 3
• Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic ImpairmentCompletedNCT05437120Phase 1
• Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of AgeActive, not recruitingNCT05422222Phase 3
• A Microneurography (MNG) Study of VX-150 in Healthy ParticipantsCompletedNCT05418712Phase 1
• Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)Active, not recruitingNCT05356195Phase 3
• A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy ParticipantsCompletedNCT05347394Phase 1
• Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508delActive, not recruitingNCT05331183Phase 3
• Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)Active, not recruitingNCT05329649Phase 3
• A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy ParticipantsCompletedNCT05324410Phase 1
• Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney DiseaseActive, not recruitingNCT05312879Phase 2/3
• Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and OlderCompletedNCT05153317Phase 3
• A Study of ALPN-303 in Adult Healthy VolunteersCompletedNCT05034484Phase 1
• A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic FibrosisCompletedNCT04923464
• ALPN-202 With PD-1 Inhibition in Advanced MalignanciesTerminatedNCT04920383Phase 1
• ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del MutationApproved for marketingNCT04702360
• A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)TerminatedNCT04261712Phase 2
• Mass Balance and Pharmacokinetics of [14C]-CRN00808 in Healthy VolunteersCompletedNCT04246749Phase 1
• ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHDTerminatedNCT04227938Phase 1
• An Open-label Study of ALPN-202 in Subjects With Advanced MalignanciesTerminatedNCT04186637Phase 1
• VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes)Approved for marketingNCT04058210
• A Single and Multiple-Ascending Dose Study of CRN01941 in Healthy Adult VolunteersCompletedNCT03936166Phase 1
• Cell Surface Marker Expression in Autoimmune DiseasesCompletedNCT03757065
• Adult Healthy Volunteers Study to Evaluate ALPN-101 SafetyCompletedNCT03748836Phase 1
• A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-ThalassemiaCompletedNCT03655678Phase 2/3
• A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult SubjectsCompletedNCT03486236Phase 1
• Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic FibrosisApproved for marketingNCT03278314
• Single and Multiple-Ascending Dose Study of CRN00808 in Healthy VolunteersCompletedNCT03276858Phase 1
• A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes MellitusCompletedNCT03162926Phase 1
• A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic FibrosisCompletedNCT03029455Phase 1
• One-Year Follow-up Safety Study in Subjects Previously Implanted With VC-01™CompletedNCT02939118
• MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)CompletedNCT02934139Phase 1
• Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With IvacaftorStatus unknownNCT02724527Phase 2
• A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric PatientsCompletedNCT02722057
• A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the KneeCompletedNCT02660424Phase 2
• Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR MutationCompletedNCT02589236Phase 2
• A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult SubjectsCompletedNCT02500667Phase 1
• Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)CompletedNCT02445053
• Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR MutationCompletedNCT02275936Phase 1
• PK Study of N91115 in Cystic Fibrosis PatientsCompletedNCT02227888Phase 1
• An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With IvacaftorCompletedNCT02015507Phase 1
• Phase 1, QT/QTC Interval Study in Healthy SubjectsCompletedNCT01910415Phase 1
• A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With IvacaftorCompletedNCT01899105Phase 1
• Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy SubjectsCompletedNCT01888393Phase 1
• Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male SubjectsCompletedNCT01886209Phase 1
• An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic FibrosisCompletedNCT01863238
• A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis CCompletedNCT01842451Phase 2
• A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid ArthritisCompletedNCT01830985Phase 2/3
• A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult SubjectsCompletedNCT01768663Phase 1
• A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 InhibitorCompletedNCT01754935Phase 2
• A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis CCompletedNCT01726946Phase 2
• 24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking MethotrexateCompletedNCT01590459Phase 2
• VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis CCompletedNCT01581138Phase 2
• A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza VirusCompletedNCT01561807Phase 2
• A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated CirrhosisCompletedNCT01516918Phase 2
• A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy SubjectsCompletedNCT01511432Phase 1
• A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial EpilepsyTerminatedNCT01501383Phase 2
• VX-770 Expanded Access ProgramApproved for marketingNCT01381289
• Drug-Drug Interaction Study Between Telaprevir and BuprenorphineCompletedNCT01275599Phase 1
• Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy SubjectsCompletedNCT01216046Phase 1
• Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy SubjectsCompletedNCT01208285Phase 1
• Study of VX-770 on DesipramineCompletedNCT01153542Phase 1
• Study of VX-985 in Subjects With Chronic Hepatitis CCompletedNCT01144936Phase 1
• A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus InfectionTerminatedNCT01080222Phase 2
• Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770CompletedNCT01060566Phase 1
• A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid ArthritisCompletedNCT01052194Phase 2
• Study of VX-765 in Subjects With Treatment-resistant Partial EpilepsyCompletedNCT01048255Phase 2
• A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy AdultsCompletedNCT01038167Phase 1
• Study of VX-770 and Rifampin in Healthy Male SubjectsCompletedNCT01018368Phase 1
• Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy SubjectsCompletedNCT00966602Phase 1
• Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy SubjectsCompletedNCT00958152Phase 1
• A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid TumorsWithdrawnNCT00923728Not applicable
• Virology Follow up Study in Subjects Previously Treated With TelaprevirCompletedNCT00916474
• Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C InfectionCompletedNCT00911963Phase 1/2
• Single and Multiple Dose Escalation Study of VX-509 in Healthy SubjectsCompletedNCT00789126Phase 1
• Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C InfectionCompletedNCT00623649Phase 1
• Study of Telaprevir in Subjects With Hepatic ImpairmentCompletedNCT00509210Phase 1
• A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord InjuriesCompletedNCT00500812Phase 1/2
• AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic CancerTerminatedNCT00493441Phase 2
• A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702CompletedNCT00395577Phase 2
• A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.CompletedNCT00389298Phase 1/2
• Trial of AVN-944 in Patients With Advanced Hematologic MalignanciesCompletedNCT00273936Phase 1
• Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis CCompletedNCT00262483Phase 2
• Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic RecipientsTerminatedNCT00260234Phase 1/2
• VX-950 and Peginterferon for Hepatitis CCompletedNCT00251199Phase 1
• Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702CompletedNCT00205478Phase 2
• Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765CompletedNCT00205465Phase 2
• Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis CCompletedNCT00088504Phase 2
• VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung CancerTerminatedNCT00003847Phase 2

← Vertex Pharmaceuticals Incorporated overview and focus areas